Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines

16 Feb 2020

Abstract excerpt

Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32079091
DOI: 10.3390/cancers12020455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell LinesPMID 32079091Read ↗

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.Semantic proximity Read ↗

Pathway-Directed Therapy in Multiple MyelomaSemantic proximity Read ↗

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.Semantic proximity Read ↗

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaSemantic proximity Read ↗

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read ↗

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple MyelomaSemantic proximity Read ↗

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.Semantic proximity Read ↗

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read ↗

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activationSemantic proximity Read ↗

Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma ModelSemantic proximity Read ↗

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Semantic proximity Read ↗

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.